On June 30 2023, INOGEN ($NASDAQ:INGN) reported their Q2 FY2023 earnings results with total revenue of USD 83.6 million, a decrease of 19.1% from the same quarter a year prior. Net income for the quarter was USD -9.8 million, compared to -3.4 million in Q2 FY2022.
Analysis – Inogen Stock Fair Value Calculator
GoodWhale has performed an analysis of INOGEN‘s wellbeing and the results are very impressive. According to GoodWhale’s data, the intrinsic value of INOGEN’s shares is estimated to be around $25.4, which was determined through GoodWhale’s proprietary Valuation Line. This implies that the current trading price of the stock, which is $7.5, is significantly lower than its true value and is undervalued by a whopping 70.5%. This makes INOGEN a great option for investors looking to get a good return on their investments. The reason behind this massive underpricing could be the lack of awareness about the stock in the market. Despite its high intrinsic value, the stock is still undervalued by a large margin. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Inogen. INOGEN_Reports_Q2_FY2023_Earnings_with_19.1_Decrease_in_Revenue_from_Prior_Year”>More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Inogen. INOGEN_Reports_Q2_FY2023_Earnings_with_19.1_Decrease_in_Revenue_from_Prior_Year”>More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Inogen. INOGEN_Reports_Q2_FY2023_Earnings_with_19.1_Decrease_in_Revenue_from_Prior_Year”>More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Inogen are shown below. INOGEN_Reports_Q2_FY2023_Earnings_with_19.1_Decrease_in_Revenue_from_Prior_Year”>More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Inogen Inc, a medical device company, competes with Inspire Medical Systems Inc, NuVasive Inc, and Globus Medical Inc in the market for minimally invasive medical devices. The company’s products include oxygen concentrators and portable oxygen systems. Inogen Inc has a market share of xx% of the minimally invasive medical devices market.
– Inspire Medical Systems Inc ($NYSE:INSP)
Inspire Medical Systems Inc is a medical device company that specializes in the treatment of sleep apnea. The company’s market cap as of 2022 is 5.27B and its ROE is -11.49%.
NuVasive Inc is a medical device company that develops and markets minimally invasive products and services for spine surgery. It has a market capitalization of 2.29 billion as of 2022 and a return on equity of -1.33%. The company’s products and services are used in spine surgery procedures such as pedicle screw fixation, interbody fusion, and vertebroplasty.
– Globus Medical Inc ($NYSE:GMED)
Globus Medical Inc is a medical device company that focuses on developing and commercializing musculoskeletal technologies. The company was founded in 2003 and is headquartered in Audubon, Pennsylvania. As of 2022, Globus Medical Inc has a market cap of 6.65B and a Return on Equity of 7.02%. The company’s products are used by orthopedic surgeons to treat a variety of conditions, including degenerative disc disease, scoliosis, and deformities.
INOGEN‘s Q2 FY2023 earnings results showed a decrease in total revenue from the previous year, amounting to USD 83.6 million. Net income for the quarter was a loss of USD -9.8 million, which was substantially larger than the -3.4 million reported in Q2 FY2022. For investors, this signals a need for further analysis of INOGEN’s performance and future prospects before investing. Analysts should review financial trends, competitive landscape, and other key metrics of the company to make an informed decision.